TW200457B - - Google Patents

Download PDF

Info

Publication number
TW200457B
TW200457B TW080106873A TW80106873A TW200457B TW 200457 B TW200457 B TW 200457B TW 080106873 A TW080106873 A TW 080106873A TW 80106873 A TW80106873 A TW 80106873A TW 200457 B TW200457 B TW 200457B
Authority
TW
Taiwan
Prior art keywords
patent application
compound
page
standards
ministry
Prior art date
Application number
TW080106873A
Other languages
English (en)
Chinese (zh)
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of TW200457B publication Critical patent/TW200457B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
TW080106873A 1990-08-29 1991-08-29 TW200457B (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57471090A 1990-08-29 1990-08-29
US07/735,700 US5189179A (en) 1990-08-29 1991-07-30 Serotonin 5ht1a agonists

Publications (1)

Publication Number Publication Date
TW200457B true TW200457B (https=) 1993-02-21

Family

ID=27076473

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080106873A TW200457B (https=) 1990-08-29 1991-08-29

Country Status (21)

Country Link
US (3) US5189179A (https=)
EP (1) EP0478954B1 (https=)
JP (1) JPH04270264A (https=)
KR (1) KR920004345A (https=)
CN (1) CN1030766C (https=)
AT (1) ATE197040T1 (https=)
AU (1) AU641535B2 (https=)
CA (1) CA2049803A1 (https=)
DE (1) DE69132450T2 (https=)
DK (1) DK0478954T3 (https=)
ES (1) ES2153346T3 (https=)
FI (1) FI914065L (https=)
GR (1) GR3035062T3 (https=)
HU (1) HU208955B (https=)
IE (1) IE913036A1 (https=)
IL (1) IL99306A (https=)
NO (1) NO175430C (https=)
NZ (1) NZ239521A (https=)
PH (1) PH30242A (https=)
PT (1) PT98800B (https=)
TW (1) TW200457B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6406859B1 (en) * 1992-01-08 2002-06-18 Synaptic Pharmaceutical Corporation DNA encoding a 5-HT 1F receptor and uses thereof
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9304632D0 (en) * 1993-03-06 1993-04-21 Wyeth John & Brother Ltd Amide derivatives
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
NZ325914A (en) 1996-03-29 1999-09-29 Pfizer Benzyl(idene)-lactam derivatives and salts thereof, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors and thus are effective as psychotherapeutic agents
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6121307A (en) * 1998-04-08 2000-09-19 American Home Products Corp. N-aryloxyethyl-indoly-alkylamines for the treatment of depression
ATE227718T1 (de) * 1998-04-08 2002-11-15 Wyeth Corp N-aryloxyethyl-indolyl-alkylamine zur behandlung von depressionen
AU3386199A (en) * 1998-04-08 1999-10-25 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
CN1304409A (zh) * 1998-04-08 2001-07-18 美国家用产品公司 用于治疗抑郁症的吲哚－3－基－环己胺衍生物(5－ht1受体拮抗剂)
US6150533A (en) * 1998-04-08 2000-11-21 American Home Products Corp. N-aryloxyethyl-indoly-alkylamines for the treatment of depression
US7588029B2 (en) * 2000-03-21 2009-09-15 Fisher & Paykel Healthcare Limited Humidified gases delivery apparatus
AU2002325712C1 (en) 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
JP4906231B2 (ja) * 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
WO2003024471A2 (en) * 2001-09-18 2003-03-27 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
WO2004011497A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
WO2004060355A1 (en) * 2002-12-26 2004-07-22 Pozen Inc. Multilayer Dosage Forms Containing NSAIDs and Triptans
JP2006527195A (ja) * 2003-06-06 2006-11-30 グラクソ　グループ　リミテッド トリプタンおよびｎｓａｉｄを含む組成物
WO2005018541A2 (en) * 2003-07-11 2005-03-03 Pharmacia Corporation Cox-2 inhibitor and serotonin modulator for treating cns damage
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
CA2536340A1 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
CN1325673C (zh) * 2003-12-30 2007-07-11 上海交通大学 利用废旧紫铜生产无氧铜的装置
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US7534765B2 (en) 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
KR20080103108A (ko) 2006-03-17 2008-11-26 스템 셀 테라퓨틱스 코포레이션 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN111116451A (zh) * 2020-01-16 2020-05-08 宁波大学 一种多取代色胺基苯甲酰胺类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2725386A (en) * 1953-02-13 1955-11-29 Fond Emanuele Paterno 2-(1, 4-benzodioxan) methyl derivatives of amino-lower fatty acid amides and preparation thereof
FR2463765A1 (fr) * 1979-08-17 1981-02-27 Clin Midy Nouveaux derives de l'indole actifs sur le systeme cardiovasculaire
US4684739A (en) * 1980-12-15 1987-08-04 Mitsubishi Chemical Industries Limited Alkylenedioxybenzene derivatives and acid addition salts thereof
US4614807A (en) * 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
DE3771280D1 (de) * 1986-06-26 1991-08-14 Ciba Geigy Ag Hydrierte 1-benzooxacycloalkyl-pyridincarbonsaeureverbindungen.
DE3642497A1 (de) 1986-12-12 1988-06-23 Hoechst Ag Substituierte aminopropionsaeureamide, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung sowie die bei der herstellung anfallenden neuen zwischenprodukte
US4956382A (en) * 1987-02-07 1990-09-11 Pfizer Inc. Sulfonamide anti-arrhythmic agents
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5120758A (en) * 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors

Also Published As

Publication number Publication date
NO175430B (no) 1994-07-04
AU641535B2 (en) 1993-09-23
IL99306A (en) 1995-03-30
HUT59092A (en) 1992-04-28
DK0478954T3 (da) 2001-01-08
IL99306A0 (en) 1992-07-15
FI914065A7 (fi) 1992-03-01
CA2049803A1 (en) 1992-03-01
CN1059717A (zh) 1992-03-25
NO913384D0 (no) 1991-08-28
NO913384L (no) 1992-03-02
ES2153346T3 (es) 2001-03-01
ATE197040T1 (de) 2000-11-15
KR920004345A (ko) 1992-03-27
US5387604A (en) 1995-02-07
US5189179A (en) 1993-02-23
AU8266491A (en) 1992-03-05
JPH04270264A (ja) 1992-09-25
FI914065A0 (fi) 1991-08-28
HU208955B (en) 1994-02-28
US5559143A (en) 1996-09-24
PH30242A (en) 1997-02-05
NO175430C (no) 1994-10-12
PT98800B (pt) 1999-01-29
NZ239521A (en) 1993-07-27
PT98800A (pt) 1992-08-31
CN1030766C (zh) 1996-01-24
DE69132450D1 (de) 2000-11-23
FI914065L (fi) 1992-03-01
IE913036A1 (en) 1992-03-11
GR3035062T3 (en) 2001-03-30
DE69132450T2 (de) 2001-05-03
EP0478954A1 (en) 1992-04-08
EP0478954B1 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
TW200457B (https=)
US5637593A (en) Tryptamine analogues as 5-ht1-like agonists
TW593278B (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
Spadoni et al. Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study
JP2009523734A (ja) ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール
TW201211010A (en) Novel heterocyclic derivative and pharmaceutical composition comprising the same
TW201002323A (en) Novel piperazine salts as D3/D2 antagonists
TW201211030A (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
MXPA05004128A (es) 4-piperazinil bencenosulfonil indoles con afinidad al receptor 5-hidroxitriptamina 6 (5-ht6).
JP2007502272A (ja) ５‐ＨＴ２Ｃ受容体アゴニストとしての６‐（２，２，２‐トリフルオロエチルアミノ）‐７‐クロロ‐２，３，４，５‐テトラヒドロ‐１Ｈ‐ベンゾ［ｄ］アゼピン
JP2003524571A (ja) インドール−及び２，３−ジヒドロインドール誘導体、その製造方法及びその使用方法
CA2264080A1 (en) 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
MXPA06001229A (es) Derivados de 1-sulfonilindol, su preparacion y su uso como ligandos de 5-ht6.
JP2003519224A (ja) 置換されたフェニル−ピペラジン誘導体、その製造方法及びその使用方法
JPH06502165A (ja) 治療上有用な２−アミノテトラリン誘導体
AU2009232836A1 (en) Indolinone compound
JP2003522720A (ja) Ｎ−ヘテロ環グリオキサミド化合物を用いたアポトーシス関連疾患の治療方法
AU2017300841B2 (en) Imidazolyl-substituted indole derivatives binding 5-HT7 serotonin receptor and pharmaceutical compositions thereof
JPH08506357A (ja) ５−ｈｔ１ｄ選択性を有するトリプトアミン類似体
CA2485537A1 (en) Novel compounds, their use and preparation
TW215088B (https=)
WO2006088954A1 (en) Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms
CN101263112B (zh) 组胺h3受体药物、其制备和治疗用途
JP2002510675A (ja) うつ病治療用のｎ−アリールオキシエチル−インドリル−アルキルアミン（５−ｈｔ１ａ受容体活性薬）
Iakovou et al. Design, synthesis and biological evaluation of novel β-substituted indol-3-yl ethylamido melatoninergic analogues